Log in to save to my catalogue

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreat...

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreat...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8377319

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX

About this item

Full title

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX

Publisher

London, England: SAGE Publications

Journal title

Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211033704-17588359211033704

Language

English

Formats

Publication information

Publisher

London, England: SAGE Publications

More information

Scope and Contents

Contents

Background:
Biomarkers predicting treatment response may be used to stratify pancreatic ductal adenocarcinoma (PDAC) patients for therapy. The aim of this study was to identify circulating tumor DNA (ctDNA) mutations that associate with tumor progression during FOLFIRINOX chemotherapy, and overall survival (OS).
Methods:
Circulating cell-f...

Alternative Titles

Full title

Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8377319

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8377319

Other Identifiers

ISSN

1758-8359,1758-8340

E-ISSN

1758-8359

DOI

10.1177/17588359211033704

How to access this item